https://scholars.lib.ntu.edu.tw/handle/123456789/628471
標題: | Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis | 作者: | Matsubara, Nobuaki Nishimura, Kazuo Kawakami, Satoru Joung, Jae Young Uemura, Hiroji Goto, Takayuki Kwon, Tae Gyun Sugimoto, Mikio Kato, Masashi Wang, Shian-Shiang Pang, See-Tong CHUNG-HSIN CHEN Fujita, Tomoko Nii, Masahiro Shen, Liji Dujka, Melanie Hussain, Maha de Bono, Johann |
關鍵字: | BRCA; PROfound; homologous recombination repair gene alteration; mCRPC; olaparib | 公開日期: | 5-五月-2022 | 出版社: | OXFORD UNIV PRESS | 卷: | 52 | 期: | 5 | 起(迄)頁: | 441 | 來源出版物: | Japanese journal of clinical oncology | 摘要: | The Phase III PROfound study (NCT02987543) evaluated olaparib versus abiraterone or enzalutamide (control; randomized 2:1 to olaparib or control) in men with homologous recombination repair gene alterations and metastatic castration-resistant prostate cancer whose disease progressed on prior next-generation hormonal agent. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/628471 | ISSN: | 0368-2811 | DOI: | 10.1093/jjco/hyac015 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。